Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TL0017 |
Aristolactam AIIIa
|
MAPK; CDK | Cell Cycle/Checkpoint; MAPK |
Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. |